ANZCTR search results

This study aims to document the rate of renal response and reversal of renal impairment secondary to untreated multiple myeloma (MM) following treatment with Bortezomib and Dexamethasone. This will be done by blood analysis. Patients with untreated multiple myeloma will be selected by physicians. To ensure eligibility to go on trial the patients are required to undergo various blood tests, bone marrow aspirate ad doctor's review before commencing on this treatment. Who is it for? You may be eligible for this study if you are 18 years and over, have renal impairment secondary to MM, defined as a calculated estimated GFR <50ml/min. You must also provide written informed consent prior to the start of study-related procedures. Further details as to whether you are eligible for this study can be found in the inclusion and exclusion criteria within this trial record. Trial details Once you are deemed eligible to take part in this study, you will commence a 21 day cycle of Bortezomib 1.3mg/m2 IV given on days 1, 4, 8, and 11 and Dexamethasone 20mg oral on days 2, 4, 5, 8, 9, 11 and 12 on a 21 day cycle. If your disease does not achieve at least a partial remission after 2 cycles of therapy or shows disease progression at any time, you will be withdrawn from the trial. If you are eligible for high-dose chemotherapy conditioned stem cell transplant and have been responding to therapy, you will receive 4 cycles of therapy before proceeding to your transplant. If you are not eligible for a transplant, you will receive a maximum of 11 cycles of therapy except if you complete remission sooner, in which case you will have Bortezomib therapy ceased after two further cycles and therefore may receive less than 11 cycles of therapy. Treatment efficacy will be monitored throughout the study, at the end of each cycle and at the discretion of your treating doctors.

Cognitive control and spatial attention are skills that allows us to interpret and act in our environment. Although these skills are important, little is understood about the neurochemical processes that are important to cognitive control and spatial attention. This study will allow us to assess the importance of different brain chemicals in contributing to spatial attention and cognitive function.

Attentional processing is a cognitive skill that allows us to interpret and act in our environment. Although this skill is important, little is understoond about the neurochemical processes that are important to attention. This study will allow us to assess the importance of different brain chemicals in contributing to selective attention function.

This is a proposal to conduct a prospective nonrandomised open trial to assess the effectiveness, safety and efficacy of corneal cross linking in juvenile patients with progressive keratoconus who undergo either low power-long time (LPLT) versus high power-Short time (HPST) corneal cross linking in an attempt to stabilize their keratoconus. Data existing in the patient's notes prior to recruitment will form part of the data collection process.

Prospective data collection of details of venous malformations and blood screen for coagulopathy

A post stem cell transplant maintenance study with lenalidomide in combination with alternate day prednisolone. All patients will be registered prior to stem cell transplant, be planned for single high dose Melphalan-conditioned stem cell transplant and have no evidence of disease progression at re-staging 6 weeks post transplant. Oral lenalidomde will commence at a dose of 10mg daily. After 2 months following commencement, escalation or reduction of lenalidomide can be made at the discretion of the treating doctor, depending on tolerance or intolerance of the treatment. Alternate day prednisolone will commence at a dose of 50mg on alternate days with lenalidomide. No dose escalation of prednisolone is planned. Dose reductions are permitted to manage any side effects according to the study protocol. This treatment will continue until unacceptable side effects or disease relapse/progressive disease. Pre transplant, all patients will undergo disease restaging with blood tests and bone marrow aspirate. Bloods for serum storage for DNA analysis will be obtained. 6 weeks post transplant patients with adequate recovery will undergo rstaging of their disease with blood testing and bone marrow, to confirm continuing disease response. Patients with disease progression evident on re-staging will not be eligible for treatment on this study. On study, all patients will continue to be evaluated every 4 weeks with repeat blood testsfor response and monitoring until disease progression.

Certain risk factors are known to be associated with a predictably high rate of surgical wound infection following minor dermatological procedures such as skin lesion excision. The use of oral antibiotic prophylaxis has been suggested as one way of reducing this risk of infection. This project seeks to test the efficacy of such recommendations in the form of a double blind randomised control trial. For the purposes of this trial the high risk group was defined as patients undergoing skin lesion excisions from the lower limb and groin and diabetics having skin lesion excisions from any site. The intervention will consist of a 2g oral dose of cephalexin administered 30-60 minutes prior to the excision while the control will be an identical placebo. Wounds will be assessed for infection using a standardised criteria when patients return for suture removal or earlier if participants re-present due to perceived infection. A wound grading system will also be used and other information which may correlate with infection will also be recorded. This project aims to enrol 100 patients and is a pilot for a large scale multi-centre trial currently in planning.

The aim of this project is to evaluate and compare patients' physiological, functional and psychosocial recovery after three forms of radical prostatectomy surgery (open radical retropubic prostatectomy and two approaches to minimally invasive surgery: robotic-assisted radical prostatectomy and laparoscopic radical prostatectomy) for localised prostatic cancer. Recovery will be evaluated using repeated measures during three key transitions: acute (time in hospital), intermediate (7 days and 4 weeks after surgery) and long term (3 months, 6 months, 12, 18 and 24 months post surgery). The three cohorts of patients will be matched for age and prostate cancer-related criteria. Baseline preoperative assessment of patients will include: demographic characteristics, functional status including urinary and sexual function, and psychosocial status. Recovery variables will include repeated measures of: pain intensity and quality, wound healing, functional and psychosocial status.

This study will randomise all patients with 5-15% mid dermal burns attending the BPTC for first review with LDI confirmation of a mid-dermal burn into two groups; Group 1 will have Biobrane and Acticoat dressings to burn wounds and group 2 will have the regularly used acticoat dressings alone, in the conventional manner. Burns will undergo standard ward hydrodebridement or OT hydrodebridement (if necessary for analgesia). Biobrane will be secured with hypafix on the ward or rarely, if necessary in OT with staples. Both groups will then be reviewed at regular dressing changes according to the usual practise at CHW for whichever Acticoat is used. Biobrane will be removed at D14 and decision on healing made then clinically and with a Vapourometer. Scar outcome and need for grafting will be assessed as well as cost effectiveness, healing time and amount of pain at dressing changes. We feel that this study may improve clinical care by providing evidence to support the use of Biobrane and the benefits to its use will in the long term outweigh the extra costs involved.

This study will help us answer the question: Should children with acute or chronic cough be given inhaled corticosteroids to promote faster recovery and improve ability for children to return to their normal daily routines? This study will also look at what viruses may be contributing to cough in children and how cough impacts on the quality of life of children and their families.